{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:14:29Z","timestamp":1791648869187,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,2,15]],"date-time":"2014-02-15T00:00:00Z","timestamp":1392422400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s10067-014-2517-2","type":"journal-article","created":{"date-parts":[[2014,2,13]],"date-time":"2014-02-13T20:27:30Z","timestamp":1392323250000},"page":"451-459","source":"Crossref","is-referenced-by-count":244,"title":["The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain"],"prefix":"10.1007","volume":"33","author":[{"given":"Jarred","family":"Younger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Parkitny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McLain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,15]]},"reference":[{"issue":"1","key":"2517_CR1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/BF02431530","volume":"96","author":"JD Greeley","year":"1988","unstructured":"Greeley JD, L\u00ea AD, Poulos CX, Cappell H (1988) \"Paradoxical\" analgesia induced by naloxone and naltrexone. Psychopharmacology (Berlin) 96(1):36\u201339","journal-title":"Psychopharmacology (Berlin)"},{"key":"2517_CR2","doi-asserted-by":"crossref","unstructured":"Burns LH, Wang HY (2010) Ultra-low-dose naloxone or naltrexone to improve opioid analgesia: the history, the mystery and a novel approach clinical medicine insights","DOI":"10.4137\/CMT.S4870"},{"issue":"3","key":"2517_CR3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1517\/14740338.2013.783564","volume":"12","author":"M Davis","year":"2013","unstructured":"Davis M, Goforth HW, Gamier P (2013) Oxycodone combined with opioid receptor antagonists: efficacy and safety. Expert Opin Drug Saf 12(3):389\u2013402","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"2517_CR4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1176\/ajp.131.6.646","volume":"131","author":"RB Resnick","year":"1974","unstructured":"Resnick RB, Volavka J, Freedman AM, Thomas M (1974) Studies of EN-1639A (naltrexone): a new narcotic antagonist. Am J Psychiatry 131(6):646\u2013650","journal-title":"Am J Psychiatry"},{"issue":"3\u20134","key":"2517_CR5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/00952997509005661","volume":"2","author":"K Verebey","year":"1975","unstructured":"Verebey K, Mul\u00e9 SJ (1975) Naltrexone pharmacology, pharmacokinetics, and metabolism: current status. Am J Drug Alcohol Abuse 2(3\u20134):357\u2013363","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"3","key":"2517_CR6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/med.2610020302","volume":"2","author":"MS Gold","year":"1982","unstructured":"Gold MS, Dackis CA, Pottash AL, Sternbach HH, Annitto WJ, Martin D, Dackis MP (1982) Naltrexone, opiate addiction, and endorphins. Med Res Rev 2(3):211\u2013246","journal-title":"Med Res Rev"},{"issue":"7","key":"2517_CR7","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s10620-011-1653-7","volume":"56","author":"JP Smith","year":"2011","unstructured":"Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, Zagon IS (2011) Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn\u2019s disease: a randomized placebo-controlled trial. Dig Dis Sci 56(7):2088\u20132097","journal-title":"Dig Dis Sci"},{"issue":"2","key":"2517_CR8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.22006","volume":"68","author":"BA Cree","year":"2010","unstructured":"Cree BA, Kornyeyeva E, Goodin DS (2010) Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol 68(2):145\u2013150","journal-title":"Ann Neurol"},{"issue":"2","key":"2517_CR9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.37734","volume":"65","author":"J Younger","year":"2013","unstructured":"Younger J, Noor N, McCue R, Mackey S (2013) Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum 65(2):529\u2013538","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2517_CR10","first-page":"56","volume":"19","author":"B Bihari","year":"2013","unstructured":"Bihari B (2013) Bernard Bihari, MD: low-dose naltrexone for normalizing immune system function. Altern Ther Health Med 19(2):56\u201365","journal-title":"Altern Ther Health Med"},{"issue":"1\u20132","key":"2517_CR11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/0006-8993(89)91562-X","volume":"480","author":"IS Zagon","year":"1989","unstructured":"Zagon IS, McLaughlin PJ (1989) Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors. Brain Res 480(1\u20132):16\u201328","journal-title":"Brain Res"},{"issue":"4","key":"2517_CR12","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1572-0241.2007.01045.x","volume":"102","author":"JP Smith","year":"2007","unstructured":"Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS (2007) Low-dose naltrexone therapy improves active Crohn\u2019s disease. Am J Gastroenterol 102(4):820\u2013828","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"2517_CR13","doi-asserted-by":"crossref","first-page":"907","DOI":"10.4065\/mcp.2011.0206","volume":"86","author":"DJ Clauw","year":"2011","unstructured":"Clauw DJ, Arnold LM, McCarberg BH, FibroCollaborative (2011) The science of fibromyalgia. Mayo Clin Proc 86(9):907\u2013911","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2517_CR14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/138161206775193208","volume":"12","author":"DJ Wallace","year":"2006","unstructured":"Wallace DJ (2006) Is there a role for cytokine based therapies in fibromyalgia. Curr Pharm Des 12(1):17\u201322","journal-title":"Curr Pharm Des"},{"issue":"4","key":"2517_CR15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1526-4637.2009.00613.x","volume":"10","author":"J Younger","year":"2009","unstructured":"Younger J, Mackey S (2009) Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med 10(4):663\u2013672","journal-title":"Pain Med"},{"issue":"2","key":"2517_CR16","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1124\/jpet.106.118810","volume":"321","author":"D Wang","year":"2007","unstructured":"Wang D, Sun X, Sadee W (2007) Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. J Pharmacol Exp Ther 321(2):544\u2013552","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2517_CR17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bbi.2006.10.011","volume":"21","author":"LR Watkins","year":"2007","unstructured":"Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF (2007) Norman cousins lecture. Glia as the \"bad guys\": implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun 21(2):131\u2013146","journal-title":"Brain Behav Immun"},{"issue":"Pt 1","key":"2517_CR18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1242\/jeb.073411","volume":"216","author":"RH McCusker","year":"2013","unstructured":"McCusker RH, Kelley KW (2013) Immune-neural connections: how the immune system\u2019s response to infectious agents influences behavior. J Exp Biol 216(Pt 1):84\u201398","journal-title":"J Exp Biol"},{"key":"2517_CR19","doi-asserted-by":"crossref","unstructured":"Dantzer R (2007) Twenty years of research on cytokine-induced sickness behavior Brain, behavior, and immunity","DOI":"10.1016\/j.bbi.2006.09.006"},{"issue":"Suppl 1","key":"2517_CR20","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/S0889-1591(02)00077-6","volume":"17","author":"KW Kelley","year":"2003","unstructured":"Kelley KW, Bluth\u00e9 RM, Dantzer R, Zhou JH, Shen WH, Johnson RW, Broussard SR (2003) Cytokine-induced sickness behavior. Brain Behav Immun 17(Suppl 1):S112\u2013S118","journal-title":"Brain Behav Immun"},{"issue":"2","key":"2517_CR21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bbi.2004.08.004","volume":"19","author":"J Wieseler-Frank","year":"2005","unstructured":"Wieseler-Frank J, Maier SF, Watkins LR (2005) Immune-to-brain communication dynamically modulates pain: physiological and pathological consequences. Brain Behav Immun 19(2):104\u2013111","journal-title":"Brain Behav Immun"},{"issue":"1","key":"2517_CR22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1460-9568.2008.06321.x","volume":"28","author":"MR Hutchinson","year":"2008","unstructured":"Hutchinson MR et al (2008) Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci 28(1):20\u201329","journal-title":"Eur J Neurosci"},{"issue":"2","key":"2517_CR23","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0022-3565(24)39275-4","volume":"293","author":"B Liu","year":"2000","unstructured":"Liu B, Du L, Hong JS (2000) Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 293(2):607\u2013617","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20132","key":"2517_CR24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0006-8993(99)02267-2","volume":"854","author":"RC Chang","year":"2000","unstructured":"Chang RC, Rota C, Glover RE, Mason RP, Hong JS (2000) A novel effect of an opioid receptor antagonist, naloxone, on the production of reactive oxygen species by microglia: a study by electron paramagnetic resonance spectroscopy. Brain Res 854(1\u20132):224\u2013229","journal-title":"Brain Res"},{"issue":"9","key":"2517_CR25","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.jacc.2006.07.036","volume":"48","author":"SL Liu","year":"2006","unstructured":"Liu SL, Li YH, Shi GY, Chen YH, Huang CW, Hong JS, Wu HL (2006) A novel inhibitory effect of naloxone on macrophage activation and atherosclerosis formation in mice. J Am Coll Cardiol 48(9):1871\u20131879","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"2517_CR26","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1016\/0024-3205(83)90325-9","volume":"32","author":"RJ Valentino","year":"1983","unstructured":"Valentino RJ, Katz JL, Medzihradsky F, Woods JH (1983) Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists. Life Sci 32(25):2887\u20132896","journal-title":"Life Sci"},{"issue":"5","key":"2517_CR27","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jpain.2012.02.005","volume":"13","author":"SS Lewis","year":"2012","unstructured":"Lewis SS, Loram LC, Hutchinson MR, Li CM, Zhang Y, Maier SF, Huang Y, Rice KC, Watkins LR (2012) (+)-naloxone, an opioid-inactive toll-like receptor 4 signaling inhibitor, reverses multiple models of chronic neuropathic pain in rats. J Pain 13(5):498\u2013506","journal-title":"J Pain"},{"issue":"6","key":"2517_CR28","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/bph.12028","volume":"168","author":"CW Stevens","year":"2013","unstructured":"Stevens CW, Aravind S, Das S, Davis RL (2013) Pharmacological characterization of LPS and opioid interactions at the toll-like receptor 4. Br J Pharmacol 168(6):1421\u20131429","journal-title":"Br J Pharmacol"},{"issue":"1","key":"2517_CR29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00540-012-1469-4","volume":"27","author":"H Fukagawa","year":"2013","unstructured":"Fukagawa H, Koyama T, Kakuyama M, Fukuda K (2013) Microglial activation involved in morphine tolerance is not mediated by toll-like receptor 4. J Anesth 27(1):93\u201397","journal-title":"J Anesth"},{"key":"2517_CR30","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.neuroscience.2013.07.033","volume":"250","author":"L Block","year":"2013","unstructured":"Block L, Bj\u00f6rklund U, Westerlund A, J\u00f6rneberg P, Biber B, Hansson E (2013) A new concept affecting restoration of inflammation-reactive astrocytes. Neuroscience 250:536\u2013545","journal-title":"Neuroscience"},{"key":"2517_CR31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1742-2094-9-32","volume":"9","author":"Q Wang","year":"2012","unstructured":"Wang Q, Zhou H, Gao H, Chen SH, Chu CH, Wilson B, Hong JS (2012) Naloxone inhibits immune cell function by suppressing superoxide production through a direct interaction with gp91phox subunit of NADPH oxidase. J Neuroinflammation 9:32","journal-title":"J Neuroinflammation"},{"issue":"3","key":"2517_CR32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0165-0173(01)00160-6","volume":"38","author":"IS Zagon","year":"2002","unstructured":"Zagon IS, Verderame MF, McLaughlin PJ (2002) The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev 38(3):351\u2013376","journal-title":"Brain Res Brain Res Rev"},{"issue":"2","key":"2517_CR33","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0735-1097(00)00745-2","volume":"36","author":"R Sharma","year":"2000","unstructured":"Sharma R, Rauchhaus M, Ponikowski PP, Varney S, Poole-Wilson PA, Mann DL, Coats AJ, Anker SD (2000) The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 36(2):523\u2013528","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2517_CR34","first-page":"425","volume":"6","author":"JJ Garc\u00eda","year":"2013","unstructured":"Garc\u00eda JJ, Cidoncha A, Bote ME, Hinchado MD, Ortega E (2013) Altered profile of chemokines in fibromyalgia patients. Ann Clin Biochem 6(7):425\u2013435","journal-title":"Ann Clin Biochem"},{"issue":"5","key":"2517_CR35","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00296-012-2538-6","volume":"33","author":"Y Xiao","year":"2013","unstructured":"Xiao Y, Haynes WL, Michalek JE, Russell IJ (2013) Elevated serum high-sensitivity C-reactive protein levels in fibromyalgia syndrome patients correlate with body mass index, interleukin-6, interleukin-8, erythrocyte sedimentation rate. Rheumatol Int 33(5):1259\u20131264","journal-title":"Rheumatol Int"},{"issue":"4","key":"2517_CR36","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MCG.0b013e3182702f2b","volume":"47","author":"JP Smith","year":"2013","unstructured":"Smith JP, Field D, Bingaman SI, Evans R, Mauger DT (2013) Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn\u2019s disease: a pilot study. J Clin Gastroenterol 47(4):339\u2013345","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"2517_CR37","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1177\/1352458510366857","volume":"16","author":"N Sharafaddinzadeh","year":"2010","unstructured":"Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B (2010) The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler 16(8):964\u2013969","journal-title":"Mult Scler"},{"issue":"3","key":"2517_CR38","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s11481-013-9451-y","volume":"8","author":"P Chopra","year":"2013","unstructured":"Chopra P, Cooper MS (2013) Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN). J Neuroimmune Pharm 8(3):470\u2013476","journal-title":"J Neuroimmune Pharm"},{"issue":"1","key":"2517_CR39","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1212\/WNL.0b013e31827b1aa1","volume":"80","author":"L Parkitny","year":"2013","unstructured":"Parkitny L, McAuley JH, Di Pietro F, Stanton TR, O\u2019Connell NE, Marinus J, van Hilten JJ, Moseley GL (2013) Inflammation in complex regional pain syndrome: a systematic review and meta-analysis. Neurology 80(1):106\u2013117","journal-title":"Neurology"},{"issue":"3","key":"2517_CR40","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.mehy.2008.06.048","volume":"72","author":"N Brown","year":"2009","unstructured":"Brown N, Panksepp J (2009) Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses 72(3):333\u2013337","journal-title":"Med Hypotheses"},{"issue":"2","key":"2517_CR41","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-3565(25)20595-X","volume":"232","author":"A Tempel","year":"1985","unstructured":"Tempel A, Gardner EL, Zukin RS (1985) Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation. J Pharmacol Exp Ther 232(2):439\u2013444","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2517_CR42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0169-328X(95)00119-D","volume":"33","author":"IS Zagon","year":"1995","unstructured":"Zagon IS, McLaughlin PJ (1995) Gene-peptide relationships in the developing rat brain: the response of preproenkephalin mRNA and [Met5]-enkephalin to acute opioid antagonist (naltrexone) exposure. Brain Res Mol Brain Res 33(1):111\u2013120","journal-title":"Brain Res Mol Brain Res"},{"issue":"9","key":"2517_CR43","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1258\/ebm.2011.011121","volume":"236","author":"RN Donahue","year":"2011","unstructured":"Donahue RN, McLaughlin PJ, Zagon IS (2011) Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med (Maywood) 236(9):1036\u20131050","journal-title":"Exp Biol Med (Maywood)"},{"issue":"1","key":"2517_CR44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0006-8993(87)91338-2","volume":"414","author":"V Kayser","year":"1987","unstructured":"Kayser V, Besson JM, Guilbaud G (1987) Paradoxical hyperalgesic effect of exceedingly low doses of systemic morphine in an animal model of persistent pain (Freund\u2019s adjuvant-induced arthritic rats). Brain Res 414(1):155\u2013157","journal-title":"Brain Res"},{"issue":"3","key":"2517_CR45","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pain.2006.03.008","volume":"123","author":"N Galeotti","year":"2006","unstructured":"Galeotti N, Stefano GB, Guarna M, Bianchi E, Ghelardini C (2006) Signaling pathway of morphine induced acute thermal hyperalgesia in mice. Pain 123(3):294\u2013305","journal-title":"Pain"},{"key":"2517_CR46","unstructured":"Physicians\u2019 Desk Reference 2013 (67th ed) Montvale, NJ: PDR"},{"issue":"2","key":"2517_CR47","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1515\/DMDI.1991.9.2.161","volume":"9","author":"LA Pini","year":"1991","unstructured":"Pini LA, Ferretti C, Trenti T, Ferrari A, Sternieri E (1991) Effects of long-term treatment with naltrexone on hepatic enzyme activity. Drug Metabol Drug Interact 9(2):161\u2013174","journal-title":"Drug Metabol Drug Interact"},{"issue":"5","key":"2517_CR48","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1177\/1535370213488483","volume":"238","author":"IS Zagon","year":"2013","unstructured":"Zagon IS, Donahue R, McLaughlin PJ (2013) Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer. Exp Biol Med (Maywood) 238(5):579\u2013587","journal-title":"Exp Biol Med (Maywood)"},{"issue":"Pt 4","key":"2517_CR49","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/aws072","volume":"135","author":"S Casha","year":"2012","unstructured":"Casha S, Zygun D, McGowan MD, Bains I, Yong VW, Hurlbert RJ (2012) Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain 135(Pt 4):1224\u20131236","journal-title":"Brain"},{"issue":"2","key":"2517_CR50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jpain.2010.09.002","volume":"12","author":"Q Zhou","year":"2011","unstructured":"Zhou Q, Price DD, Callam CS, Woodruff MA, Verne GN (2011) Effects of the N-methyl-D-aspartate receptor on temporal summation of second pain (wind-up) in irritable bowel syndrome. J Pain 12(2):297\u2013303","journal-title":"J Pain"},{"issue":"8","key":"2517_CR51","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.biopsych.2013.03.002","volume":"73","author":"RM Swift","year":"2013","unstructured":"Swift RM (2013) Naltrexone and nalmefene: any meaningful difference? Biol Psychiatry 73(8):700\u2013701","journal-title":"Biol Psychiatry"},{"issue":"9","key":"2517_CR52","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1445-5994.2012.02886.x","volume":"42","author":"C Tang","year":"2012","unstructured":"Tang C, Godfrey T, Stawell R, Nikpour M (2012) Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Int Med J 42(9):968\u2013978","journal-title":"Int Med J"},{"issue":"10","key":"2517_CR53","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1002\/art.22131","volume":"54","author":"AC Steere","year":"2006","unstructured":"Steere AC, Angelis SM (2006) Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum 54(10):3079\u20133086","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2517_CR54","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/molecules16021021","volume":"16","author":"DK Choi","year":"2011","unstructured":"Choi DK, Koppula S, Suk K (2011) Inhibitors of microglial neurotoxicity: focus on natural products. Molecules 16(2):1021\u20131043","journal-title":"Molecules"},{"key":"2517_CR55","volume-title":"The promise of low dose naltrexone","author":"A Moore","year":"2009","unstructured":"Moore A, Wilkinson S (2009) The promise of low dose naltrexone. McFarland, North Carolina"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2517-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-014-2517-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2517-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T17:15:55Z","timestamp":1746119755000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-014-2517-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,15]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["2517"],"URL":"https:\/\/doi.org\/10.1007\/s10067-014-2517-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,15]]}}}